Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Parallel Group, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.015% In Patients With Actinic Keratoses ON the Head (Face or Scalp) (REGION-IIb).

Next Previous
Trial Profile

A Multi-Center, Randomized, Parallel Group, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.015% In Patients With Actinic Keratoses ON the Head (Face or Scalp) (REGION-IIb).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ingenol mebutate (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms REGION-IIb

Most Recent Events

  • 08 Mar 2016 Results (n=220) of a regression analysis from this and other trial (see profile 34647) presented at the 74th Annual Meeting of the American Academy of Dermatology
  • 20 Mar 2012 Pooled efficacy and tolerability analysis presented at the 70th Annual Meeting of the American Academy of Dermatology.
  • 20 Mar 2012 Tolerability results assessing local skin responses presented at the 70th Annual Meeting of the American Academy of Dermatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top